0

Levodopa-induced Dyskinesia in Parkinson Disease: Current and Evolving Concepts

Alberto J Espay, Francesca Morgante, Aristide Merola, Alfonso Fasano, Luca Marsili, Susan H Fox, Erwan Bezard, Barbara Picconi, Paolo Calabresi, Anthony E Lang

Ann Neurol. 2018 Dec;84(6):797-811.

PMID: 30357892

Abstract:

Levodopa-induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa-to-dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergic transmission, and overstimulation of nicotinic acetylcholine receptors on dopamine-releasing axons. Delay in initiating levodopa is no longer recommended, as dyskinesia development is a function of disease duration rather than cumulative levodopa exposure. We review current and in-development treatments for peak-dose dyskinesia but suggest that improvements in levodopa delivery alone may reduce its future prevalence. Ann Neurol 2018;84:797-811.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP59927-A Levodopa Levodopa 59-92-7 Price
qrcode